Navigation Links
New Mask Study Supports CDC's Updated Guidance for Seasonal Flu Prevention Strategies
Date:9/29/2010

HAUPPAUGE, N.Y., Sept. 29 /PRNewswire/ -- Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE: CMN), announced today the publication of sponsored research that suggests a far greater infection prevention value of medical face masks, commonly referred to as surgical masks, than previously understood. The key outcome challenges conventional wisdom that a medical mask or respirator is most effective when worn by a person attempting to protect oneself from exposure to infectious matter.  Instead, if FDA-cleared medical face masks are worn at the potential source of the infection, the level of overall protection is magnified up to 300-fold.  Published in the September issue of the American Journal of Infection Control, the research study, entitled "Quantifying Exposure Risk and Mask Protection", was conducted by Keith Diaz, MD, and Gerald Smaldone, MD, PhD, at Stony Brook University Medical Center in Stony Brook, NY.

This study supports the newest Centers for Disease Control and Prevention guidelines (September 2010) on Seasonal Influenza Prevention Strategies in Healthcare Settings, which recommend the use of medical face masks to minimize potential exposure to influenza viruses in healthcare settings.  The simulated bench study examined the efficacy of N95 respirators and medical face masks in their ability to reduce exposure to infectious particles when used either as protective devices (to protect the wearer) or as "source control" devices (to control infection at the source, such as a person with flu-like symptoms).  The authors' results demonstrate "the most important factor in reducing exposure was deflection of exhaled particles at the source."  

"This evidence offers healthcare providers and public health officials new insight into the benefit of medical face masks as source control devices," said Gary Steinberg, CEO of Crosstex International.  "It was clear that medical face masks were being narrowly compared to N95 respirators for their ability to protect the wearer from the outside-in.  We wanted to better understand the value of medical face masks for source control, that is, protecting others from the inside-out," said Matt Conlon, Vice President at Cantel Medical.  While medical face masks are commonly referred to as "PPE" (Personal Protection Equipment), their original purpose was to protect the patient from acquiring an infection from the physician.  This new research is the first to quantify their important role in controlling the infection at the source and further demonstrated that a tighter fitting medical mask performs best in source control.  

The findings come in the wake of the 2009 H1N1 pandemic when there were significant complications, shortages, and debate surrounding the CDC's formal recommendation for the use of N95's by healthcare workers for protection against the H1N1 virus. Steinberg said, "This shows an exponential infection control benefit at a fraction of the cost and complexity of using N95 respirators.  As one of the few remaining U.S. manufacturers of medical masks, it is important for Crosstex to continue funding this type of independent research to address infectious disease threats through continued mask innovation. We don't overlook the fact that masks are medical devices.  We understand they can save lives and dramatically reduce costs associated with respiratory-borne infections."

About Crosstex International, Inc.

A division of Cantel Medical Corp., Crosstex manufactures a wide array of infection prevention and control products for the healthcare industry.  Founded in 1953 and headquartered in Hauppauge, New York, Crosstex sells branded and private label products including face masks, which are 100% manufactured in its FDA-registered New York facility.  Sold in more than 100 countries, Crosstex products include sterilization pouches and accessories, patient towels and bibs, eyewear, surface disinfectants and deodorizers, germicidal wipes, hand sanitizers, gloves, sponges, cotton products, needles and syringes, scalpels and blades, sharps containers, saliva ejectors and evacuator tips.  For further information, visit the Crosstex website at http://www.crosstex.com.

About Cantel Medical Corp.

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.  For further information, visit the Cantel Medical website at http://www.cantelmedical.com.


'/>"/>
SOURCE Crosstex International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
2. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
3. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
4. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
5. Independent Community Pharmacies Earn High Customer Satisfaction Scores in Latest J.D. Power and Associates National Pharmacy Study
6. 12-Month Study Reports Efficacy Rates for AMS Elevate Apical and Posterior Prolapse Repair System
7. Facelift Healing Innovation: New Study Shows Hyperbaric Oxygen Therapy Decreases Bruising in Facelifts Patients by 35%
8. Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine
11. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):